APOE4 carriers display loss of anticipatory cerebrovascular regulation across the Alzheimer's disease continuum.

29 , 50 , 51 However, the magnitude of orthostasis‐induced drops in MCAv and MAP remained consistent 28 and even showed a trend toward attenuation (lesser drop) of MCAv in MCI and AD diagnoses compared to NCs who carried APOE4 (Figure 2E ), potentially reflecting heightened sympathetic drive observed across AD progression. 52 , 53 , 54 Together, our findings extend the knowledge of AD‐related impairments and pro

also in 53,322 other papers

There were two unexpected observations involving non‐carriers in this study: (1) anticipatory MCAv tended to increase in the MCI stage of disease (Figure 2B ), though the genotype‐by‐time interaction did not reach statistical significance to warrant post hoc testing, and (2) baseline (BL1) MCAv in non‐carriers with MCI (50.5 cm/s) tended to be higher than in those with NC (45.3 cm/s) and AD (41.9 cm/s) (Figure 2A‐C ).

also in 111,027 other papers